A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Sacituzumab Govitecan-hziy (SG)

Administered intravenously

Trial Locations (15)

2010

RECRUITING

St. Vincent's Hospital - Kinghorn Cancer Center, Darlinghurst

4224

RECRUITING

John Flynn Private Hospital, Tugun

4575

RECRUITING

Sunshine Coast University Private Hospital, Birtinya

23502

RECRUITING

Virginia Oncology Associates, Norfolk

30322

RECRUITING

Winship Cancer Institute - Emory University, Atlanta

37203

RECRUITING

SCRI Oncology Partners, Nashville

RECRUITING

Tennessee Oncology, PLLC, Nashville

38138

RECRUITING

West Cancer Centre, Germantown

63110

RECRUITING

Siteman Cancer Center, St Louis

75246

RECRUITING

Texas Oncology - DFW, Dallas

90017

RECRUITING

Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

NOT_YET_RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT06926920 - A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter